The clinical management of BRCA1 and BRCA2 mutation carriers
| Autor: | Susan M. Domchek, Anthony P. Gulati |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases Ovariectomy medicine.medical_treatment Genes BRCA2 Genes BRCA1 Breast Neoplasms Chemoprevention Breast cancer medicine Anticarcinogenic Agents Humans Mass Screening Genetic Predisposition to Disease Family history skin and connective tissue diseases Intensive care medicine Germ-Line Mutation Mastectomy Genetic testing Ovarian Neoplasms Gynecology medicine.diagnostic_test business.industry Oophorectomy Cancer Prophylactic Mastectomy medicine.disease Oncology Female Ovarian cancer business Risk Reduction Behavior Tamoxifen medicine.drug |
| Zdroj: | Current Oncology Reports. 10:47-53 |
| ISSN: | 1534-6269 1523-3790 |
| Popis: | Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a strong family history of cancer. This article reviews the current evidence for risk-reducing strategies in BRCA1 and BRCA2 mutation carriers and outlines future research directions. In particular, screening controversies and current guidelines are discussed, as are issues related to prophylactic mastectomy and oophorectomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink